Carcinoma, Non-Small Cell Lung Clinical Trial
Official title:
A Phase I Study on the Safety and the Efficacy of Personalized Neoantigen-primed Dendritic Cell Vaccines for Refractory Lung Cancer
Various of immunotherapies are now widely applied in the treatment of lung cancer. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are highly suitable for the development of cancer vaccines. The study aims to evaluate the safety and efficacy of neoantigen-loaded dendritic cell (DC) vaccines for refractory lung cancer.
Cancer genome research has exploded benefits from the application of modern high-throughput
genome sequencing in the past few years. Since usually there are no common antigens expressed
on the surfaces of different kinds of tumors, neoantigens which expressed specifically in the
individual tumor are chosen to establish tumor-specific vaccines.
30 patients with refractory lung cancer would be enrolled and undergo tumor resection if all
requirements are met. The whole-exome sequencing and the bioinformatic analysis of the
resected specimens would be performed to identify the neoantigens. Then, candidate
neoantigens would be synthesized to pulse the matured DC cells. Neoantigen-primed DC vaccines
are provided to the corresponding patients. Each patient would be vaccinated 6 times in
total, one shot per week.
Patients enrolled would undergo the schemed follow-up, one time per three months. The side
effects, overall survival, and progress-free survival would be recorded. At the end of the
research, the safety and efficacy of neoantigen DC vaccines for refractory lung cancer would
be evaluated.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04486833 -
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
|
Phase 1/Phase 2 | |
| Terminated |
NCT00321308 -
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00190840 -
A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05358249 -
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Terminated |
NCT02961283 -
Study of ASN003 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT00973310 -
Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00385996 -
Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02775006 -
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
|
Phase 3 | |
| Completed |
NCT03232593 -
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
|
||
| Terminated |
NCT02590003 -
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT01514864 -
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
|
Phase 2 | |
| Completed |
NCT00070629 -
CPG 7909 Injection in Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02079636 -
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
|
Phase 1 | |
| Completed |
NCT01079520 -
Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)
|
N/A | |
| Terminated |
NCT01115803 -
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00861627 -
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
|
Phase 2 | |
| Completed |
NCT00923884 -
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
|
||
| Recruiting |
NCT04389632 -
A Study of SGN-B6A in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03603652 -
NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung
|
N/A |